- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06519279
Freezing of Gait - Clinical Outcomes Assessment (FOG-COA)
An International Multimodal Protocol for Assessing Freezing of Gait in Individuals Living with Parkinson's Disease
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: omri Batori, B.sc
- Phone Number: +972546670256
- Email: omrib@tlvmc.gov.il
Study Contact Backup
- Name: Jeffery Hausdorff, Professor
- Email: jeffh@tlvmc.gov.il
Study Locations
-
-
-
Tel aviv, Israel
- Recruiting
- Tel Aviv Saurasky Medical Center
-
Contact:
- omri Batori, B.sc
- Phone Number: +972546670256
- Email: omrib@tlvmc.gov.il
-
Contact:
- Shahar Siman Toc, B.sc
- Phone Number: +972526736689
- Email: shaharst@tlvmc.gov.il
-
Contact:
- Jeffery Hausdorff, Proffesor
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Diagnosis of idiopathic Parkinson's disease (PD) made by a neurologist according to the Movement Disorders Society guidelines;
- Able to walk independently for a distance of 10 meters, without walking aid;
- Absence of a Deep Brain Stimulator;
- Stable PD treatment in the 4 weeks prior to participation that is not expected to change in the course of the study.
- For patients with FOG: a score of ≥ 1 on the New Freezing Of Gait Questionnaire (NFOG-Q).
Exclusion Criteria:
- Occurrence of any of the following within 3 months prior to informed consent: myocardial infarction, hospitalization for unstable angina, stroke, coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI), implantation of a cardiac resynchronization therapy device (CRTD), active treatment for cancer or other malignant disease, uncontrolled congestive heart disease (NYHA class >3), acute psychosis or major psychiatric disorders or continued substance abuse, other neurological (than PD) or orthopaedic impairment that significantly impacts on gait.
- Unwilling to temporarily delay the morning anti-Parkinsonian medication.
- Preganacy and
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Freezing Of Gait Patients
15 patients with Parkinson disease with freezing of gait (group) in ON & OFF states
|
Five Oplas sensors were strategically placed on participants: one on each shin, one on each foot, and one on the lower back.
At the end of the first session, participants with FOG, will be fitted with an Axivity monitor. This is wearable sensor that will be attached to the participant's lower back (lumbar vertebrae 4-5) with hypoallergic medical tape by the researcher, and will be worn continuously for seven days. The Axivity monitor is a small (23 x 32.5 x 8.9 mm) and lightweight (11g) device that measures mobility via a tri-axial accelerometer and gyroscope and stores this data onboard, no GPS or other localization options are possible with this monitor. Participants will be given following guidelines concerning the use: The sensor is to be worn continuously during the seven-day period, i.e. also while sleeping and showering. The sensor is waterproof and can be worn during showering. |
|
Non Freezing Of Gait Patients
5 patients with Parkinson disease without freezing of gait (cohort) in ON & OFF states
|
Five Oplas sensors were strategically placed on participants: one on each shin, one on each foot, and one on the lower back.
At the end of the first session, participants with FOG, will be fitted with an Axivity monitor. This is wearable sensor that will be attached to the participant's lower back (lumbar vertebrae 4-5) with hypoallergic medical tape by the researcher, and will be worn continuously for seven days. The Axivity monitor is a small (23 x 32.5 x 8.9 mm) and lightweight (11g) device that measures mobility via a tri-axial accelerometer and gyroscope and stores this data onboard, no GPS or other localization options are possible with this monitor. Participants will be given following guidelines concerning the use: The sensor is to be worn continuously during the seven-day period, i.e. also while sleeping and showering. The sensor is waterproof and can be worn during showering. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Validate the newly-developed ClinRO
Time Frame: 12/2025
|
Rate scale of freezing of gait to detect meaningful improvement in freezing of gait.
The scale name is " Freezing Of Gait Severity Score". it consist a 8 trials, each one can be rate between 0 to 8. the scale consist a part of frequency of the freezing and part of cumulative duration.
The higher the score, the more severe the stagnation and the lower it is, the less stagnation is present.
|
12/2025
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Asses the importance of the FOG symptom for patients
Time Frame: 12/2025
|
Severity of freezing of gait (FOG) symptoms and patient-reported impact on quality of life.
The scale name is " Freezing Of Gait Severity Score". it consist a 8 trials, each one can be rate between 0 to 8. the scale consist a part of frequency of the freezing and part of cumulative duration.
The higher the score, the more severe the stagnation and the lower it is, the less stagnation is present.
|
12/2025
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0608-23-TLV
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.